OrderlyMeds Pairs GLP-1 Weight Loss Care With Biomarker Testing
Atlanta – – September 15, 2026 -- OrderlyMeds and Veo Health have launched a partnership that lets weight-loss patients track biological changes happening beneath the scale, not just the number on it.
Two new membership tiers track more than 60 biomarkers
OrderlyMeds customers can now access Veo Core, which screens 60-plus biomarkers with AI-powered insights, or Veo Pro, which expands to 80-plus biomarkers and adds physician consultations, health-advisor sessions and a personalized action plan. Veo Health members, meanwhile, get discounted access to OrderlyMeds' prescribing and clinical network.